Rick
>>We couldn't figure out if it was AN-9 itself, or a derivative.>>
Pivaloyloxymethyl butyrate, Pivanex and AN-9 are one and the same.
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG
Clin Cancer Res. 2002 Jul ; 8(7): 2142-8
Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), has demonstrated greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties than BA in preclinical studies.
pmbrowser.info
>>It supposedly entered phase II testing six years ago.>>
It might even be older. The main purpose of the drug seems to be to support Titan's funding requirements. It is - as I suppose you know - in a plus/minus 225 patient Phase IIb trial with docetaxel in NSCLC at the moment. I believe results are expected towards the end of this year.
Erik |
